DK1096016T3 - Blodpladeaktiveringsfaktor-acetylhydrolase - Google Patents

Blodpladeaktiveringsfaktor-acetylhydrolase

Info

Publication number
DK1096016T3
DK1096016T3 DK00128728T DK00128728T DK1096016T3 DK 1096016 T3 DK1096016 T3 DK 1096016T3 DK 00128728 T DK00128728 T DK 00128728T DK 00128728 T DK00128728 T DK 00128728T DK 1096016 T3 DK1096016 T3 DK 1096016T3
Authority
DK
Denmark
Prior art keywords
activating factor
factor acetylhydrolase
platelet activating
platelet
acetylhydrolase
Prior art date
Application number
DK00128728T
Other languages
English (en)
Inventor
Laurence S Cousens
Trong Hai Le
Christine D Eberhardt
Larry W Tjoelker
Cheryl L Wilder
Patrick W Gray
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Application granted granted Critical
Publication of DK1096016T3 publication Critical patent/DK1096016T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
DK00128728T 1993-10-06 1994-10-06 Blodpladeaktiveringsfaktor-acetylhydrolase DK1096016T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13380393A 1993-10-06 1993-10-06
EP94930623A EP0673426B1 (en) 1993-10-06 1994-10-06 Platelet-activating factor acetylhydrolase

Publications (1)

Publication Number Publication Date
DK1096016T3 true DK1096016T3 (da) 2006-05-29

Family

ID=22460373

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00128728T DK1096016T3 (da) 1993-10-06 1994-10-06 Blodpladeaktiveringsfaktor-acetylhydrolase
DK94930623T DK0673426T3 (da) 1993-10-06 1994-10-06 Blodpladeaktiveringsfaktor-acetylhydrolase

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94930623T DK0673426T3 (da) 1993-10-06 1994-10-06 Blodpladeaktiveringsfaktor-acetylhydrolase

Country Status (11)

Country Link
US (5) US5641669A (da)
EP (3) EP1634953A3 (da)
JP (3) JP3613398B2 (da)
AT (2) ATE315655T1 (da)
CA (1) CA2151045C (da)
DE (2) DE69427392T2 (da)
DK (2) DK1096016T3 (da)
ES (2) ES2258955T3 (da)
GR (1) GR3036535T3 (da)
PT (1) PT673426E (da)
WO (1) WO1995009921A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69423436T2 (de) * 1993-06-25 2000-09-07 Smithkline Beecham P.L.C., Brentford An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
JP3563091B2 (ja) * 1993-08-03 2004-09-08 第一サントリーファーマ株式会社 酸化リン脂質分解酵素およびその遺伝子
US6146625A (en) * 1993-10-06 2000-11-14 Icos Corporation Platelet-activating factor acetylhydrolase
JP2002515728A (ja) * 1995-09-29 2002-05-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規用途
JPH11514228A (ja) * 1995-09-29 1999-12-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー リポ蛋白結合ホスホリパーゼＡ２（Ｌｐ−ＰＬＡ２）ＰＡＦアセチルヒドロラーゼに対して配列相同性を有する化合物
JP2000502079A (ja) * 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
HUP9901359A3 (en) * 1996-04-26 2000-03-28 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them
US6166292A (en) * 1996-04-26 2000-12-26 Ajinomoto Co., Inc. Raffinose synthetase gene, method of producing raffinose and transgenic plant
US6891084B1 (en) * 1996-04-26 2005-05-10 Ajinomoto Co., Inc. DNA encoding raffinose synthase from soybean
JPH1017600A (ja) * 1996-06-28 1998-01-20 Suntory Ltd 血小板活性化因子アセチルヒドロラーゼおよびその遺伝子
BR9711882A (pt) * 1997-08-13 1999-09-21 Icos Corp Fragmento, variante ou fragmento de variante de polipeptídeo de acetilidrolase (paf-ah), polinucleotídeo isolado, vetor de dna, célula hospedeira transformada ou transfectada com um dna, processo para a produção de um fragmento, variante ou fragmento de variante de polipeptídeo de paf - ah de plasma, composição farmacêutica, e, processo para tratar um mamífero suscetível a, ou sofrendo de, um quadro patológico mediado por paf.
JP2002528084A (ja) * 1998-10-28 2002-09-03 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 固定化金属アフィニティークロマトグラフィーを用いる低密度リポタンパク質関連ホスホリパーゼａ２の精製方法
GB9923790D0 (en) * 1999-10-08 1999-12-08 Isis Innovation Immunoregulatory compositions
NZ520752A (en) 2000-02-16 2004-03-26 Smithkline Beecham P Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0027181D0 (en) * 2000-11-04 2000-12-27 S P A New use
US7468266B2 (en) * 2001-05-30 2008-12-23 Ryogen, Llc Isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2
US7475248B2 (en) 2002-04-29 2009-01-06 International Business Machines Corporation Enhanced message security
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
PL1633864T3 (pl) 2003-05-28 2010-09-30 Glaxo Group Ltd Wysokowydajny test aktywności Lp-PLA2
JP5155564B2 (ja) 2004-02-03 2013-03-06 ディアデクサス インコーポレーテッド Ｌｐ−ＰＬＡ２活性を検出する方法
US20070166777A1 (en) * 2004-04-16 2007-07-19 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
JP2007145814A (ja) * 2005-10-28 2007-06-14 Bizen Chemical Co Ltd 血小板活性化因子受容体拮抗剤および組成物
JP2009534035A (ja) * 2006-04-21 2009-09-24 ワイス 細胞系のハイスループットスクリーニング方法
EP2977452A3 (en) 2007-05-11 2016-05-25 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
CN101687009A (zh) 2007-05-11 2010-03-31 宾夕法尼亚大学理事会 治疗皮肤溃疡的方法
US8257697B2 (en) * 2007-10-31 2012-09-04 Allertech Laboratory Inc. Use of platelet activating factor acetylhydrolase as biomarker for anaphylaxis
JP2009005705A (ja) * 2008-07-02 2009-01-15 Icos Corp 血小板活性化因子アセチルヒドロラーゼ
JP5596964B2 (ja) * 2008-12-02 2014-09-24 協和メデックス株式会社 リポ蛋白中成分の分別定量用標準品の製造方法
ES2847883T3 (es) 2010-12-17 2021-08-04 Glaxo Group Ltd Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
CN105542010B (zh) * 2015-12-31 2020-11-03 武汉华美生物工程有限公司 脂蛋白相关磷脂酶a2单克隆抗体、抗体对及制备方法、用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5279957A (en) * 1992-04-30 1994-01-18 Washington University cDNA encoding human phospholipase A2 polypeptide
GB9400413D0 (en) 1994-01-11 1994-03-09 Smithkline Beecham Plc Compounds
DE69423436T2 (de) * 1993-06-25 2000-09-07 Smithkline Beecham P.L.C., Brentford An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
GB9313144D0 (en) 1993-06-25 1993-08-11 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
GR3036535T3 (en) 2001-12-31
JP2004129671A (ja) 2004-04-30
US5532152A (en) 1996-07-02
JP2006056901A (ja) 2006-03-02
DE69427392D1 (de) 2001-07-12
ES2159573T3 (es) 2001-10-16
ATE315655T1 (de) 2006-02-15
WO1995009921A1 (en) 1995-04-13
EP1634953A3 (en) 2006-06-28
JP3759941B2 (ja) 2006-03-29
US5605801A (en) 1997-02-25
HK1038587A1 (en) 2002-03-22
DE69434609T2 (de) 2006-09-21
DE69434609D1 (de) 2006-04-06
EP0673426B1 (en) 2001-06-06
ES2258955T3 (es) 2006-09-16
HK1012023A1 (en) 1999-07-23
CA2151045A1 (en) 1995-04-13
US5641669A (en) 1997-06-24
EP1634953A2 (en) 2006-03-15
DE69427392T2 (de) 2002-05-23
CA2151045C (en) 2002-04-30
EP1096016B1 (en) 2006-01-11
JPH08504603A (ja) 1996-05-21
JP3613398B2 (ja) 2005-01-26
EP0673426A1 (en) 1995-09-27
PT673426E (pt) 2001-11-30
US20050100540A1 (en) 2005-05-12
DK0673426T3 (da) 2001-08-27
EP1096016A1 (en) 2001-05-02
US5698403A (en) 1997-12-16
ATE201905T1 (de) 2001-06-15

Similar Documents

Publication Publication Date Title
DK0673426T3 (da) Blodpladeaktiveringsfaktor-acetylhydrolase
ATE155143T1 (de) 2-substituierte indan-2-mercaptoacetylamid- verbindungen mit enkephalinase und ace- hemmwirkung
ATE143972T1 (de) 2-substituierte indane-2-carboxyalkyl- verbindungen mit enkephalinase und ace- hemmwirkung
DE68928734D1 (de) Verfahren zur Herstellung alternierende Kristallstrukturen aufweisender thermoplastischer Elastomere als Bindemittel in Hochenergiezusammensetzungen
IL99769A0 (en) Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DE69411692D1 (de) Mittel zur Förderung der Proliferationen von Bifidobacterium
DE3888360D1 (de) Hochspannungsschalter und verfahren zur ansteuerung von verbrauchern mittels des hochspannungsschalters.
DE69330807D1 (de) Verfahren zur Herstellung von gereinigtem Enzym
DE59407394D1 (de) Verwendung von polyacetalen zur herstellung von kompostierbaren formkörpern
IL106748A0 (en) 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
FI885024A7 (fi) Hyytymistä estävän proteiinin PP4 valmistus geeniteknologian avulla
CA2267994A1 (en) Truncated platelet-activating factor acetylhydrolase
EP0244361A3 (en) Individual beta-form crystals of tetrakis-û3-(3,5-di-t-butyl-4-hydroxyphenyl)-propionyloxymethyl¨ methane and process for their manufacture
ATA247988A (de) Vormaterial fuer die erzeugung von verbundwerkstoffen
IT9021986A0 (it) Procedimento e mezzi per la produzione continua di corpi di carbone
FI940265A7 (fi) Jatkuvatoiminen menetelmä dimetoksietanaalin teolliseksi valmistamiseksi
FI885301A7 (fi) Tekijä VIII:n puhdistuksessa käyttökelpoisia peptidejä
ATE243924T1 (de) Herstellung von cleistogamen mutanten von kienzblütlern
DE69427794D1 (de) Verbesserungen an Erdmühlen zur Herstellung von Terrakotta-Produkten
DE69432042D1 (de) Verfahren zum Screenen von Agenzien zur Prophylaxis oder Therapie von mit IgE zusammenhängenden Krankheiten
GR3019685T3 (en) Novel 2-mercaptomethylene-tetrahydronaphthalene and indane-2-carboxamide derivatives as enkephalinase inhibitors
DE69416663D1 (de) Verfahren zur Herstellung von menschlichem Glicentin
ATE315583T1 (de) Analoge des thymosin alpha 1
ITVI920198A1 (it) Ciclo di lavorazione per la produzione di pelli tipo nabuk
ITVI930098A1 (it) Ciclo di lavorazione per la produzione di pelli tipo nabuk